Overall Risk Summary
The main risk is no longer survival; it is proof. POET must turn demos, awards, and partner announcements into recurring product revenue, acceptable yields, and broader customer adoption. The balance sheet now buys time, but it does not solve commercialization, concentration, or valuation risk. If 2026 shipments and 2027 follow-on wins land, the story improves quickly; if not, the stock can de-rate even with strong industry demand.